Ophthalmology venture grabs investors’ attention, raises $330 million
Ollin Biosciences secures $330 million to challenge Roche's Vabsymo in retina disease treatment
📍 Aftermath
Ollin Biosciences raised $330 million in an oversubscribed Series B financing round. The funds were intended to advance global Phase 3 development of OLN324 for DME and wet AMD.
These studies were scheduled to commence in the second half of 2026.
Epilogue added 20d ago, after coverage quieted.
Sources (5)
- Ollin raises $330M to dethrone Roche's Vabsymo in retina diseases FirstWord PHARMA · 34d ago
- Ollin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet Fierce Biotech · 34d ago
- Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026 Business Wire · 34d ago
- Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China Endpoints News · 34d ago
- Ophthalmology venture grabs investors’ attention, raises $330 million statnews.com · 34d ago
The brief
Ollin Biosciences has raised $330 million in Series B financing. The funds will support global Phase 3 development of OLN324, a treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD).
Coverage emphasizes the competitive landscape in ophthalmology, particularly the challenge to Roche's Vabsymo. Reports from FirstWord PHARMA, Fierce Biotech, Business Wire, Endpoints News, and statnews.com highlight Ollin's ambitious plans and the significant investment it has attracted.
Ollin's Phase 3 trials for OLN324 are set to commence in the second half of 2026. Coverage does not yet specify the trial locations or the timeline for results.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 34d ago.
Quick answers
What is Ollin Biosciences developing?
Ollin Biosciences is developing OLN324, a treatment for diabetic macular edema (DME) and wet age-related macular degeneration (AMD).
How much funding has Ollin Biosciences raised?
Ollin Biosciences has raised $330 million in Series B financing.
What is the purpose of the funding?
The funding will support the global Phase 3 development of OLN324, with trials commencing in the second half of 2026.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Persistent vision problems after COVID linked to ongoing inflammation, nerve damage
New medical findings link persistent vision impairment following mild COVID-19 cases to underlying nerve damage and systemic immune dysregulation.
A Signal of Future Alzheimer's May Be Hidden in Your Eyes
Researchers are exploring whether retinal images and AI can predict Alzheimer's risk years before symptoms appear